Recombinant SARS-CoV-2 D614G Spike His-tag, Protein CF

5 Point Mutations (D614G, R682S, R685S, K986P, V987P)
Catalog # Availability Size / Price Qty
10587-CV-100
Recombinant SARS-CoV-2 D614G Spike, His-tag Protein CF Bioactivity
2 Images
Product Details
Citations (1)
FAQs
Reviews

Recombinant SARS-CoV-2 D614G Spike His-tag, Protein CF Summary

Why choose R&D Systems SARS-CoV-2 D614G Spike Protein?

  • Val16-Lys1211 with a C-term His tag.​
  • D614G mutation​
  • Stabilizing mutations K986P and V987P promote the prefusion conformation.
  • Two mutations, R682S and R685S, eliminate a Furin protease cleavage site.
  • Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 95%.
  • Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
  • Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs. Supply agreements available, partner with us. Please contact us.
  • Most Respected, Most Cited Brand in Proteins: With over 35 years of providing the best recombinant proteins to the scientific community, R&D Systems continues to lead the industry in quality, activity, and purity.

Interested in other SARS-CoV-2 Spike proteins? View Products

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 His-tag (Catalog # 933-ZN).
Source
Human embryonic kidney cell, HEK293-derived sars-cov-2 Spike protein
Val16-Lys1211 (Asp614Gly, Arg682Ser, Arg685Ser, Lys986Pro, Val987Pro), with a C-terminal His-tag
Accession #
N-terminal Sequence
Analysis
Val16
Predicted Molecular Mass
134 kDa
SDS-PAGE
140-160 kDa, under reducing conditions.

Product Datasheets

You must select a language.

x

10587-CV

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10587-CV

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity Recombinant SARS-CoV-2 D614G Spike, His-tag Protein CF Bioactivity View Larger

Recombinant SARS-CoV-2 D614G Spike His-tag (Catalog # 10587-CV) binds Recombinant Human ACE-2 His-tag (933-ZN) in a functional ELISA.

SDS-PAGE Recombinant SARS-CoV-2 D614G Spike His-tag, Protein CF SDS-PAGE View Larger

2 μg/lane of Recombinant SARS-CoV-2 D614G Spike His-tag, Protein (Catalog # 10587-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 140-160 kDa.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: Spike

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). SARS-CoV-2 Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into the S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). A SARS-CoV-2 variant carrying the S protein amino acid (aa) change D614G has become the most prevalent form in the global pandemic and has been associated with greater infectivity and higher viral load (6,7). The S protein of SARS-CoV-2 shares 75% and 29% aa sequence identity with S protein of SARS-CoV-1 and MERS, respectively. The S Protein of the SARS-CoV-2 virus, like the SARS-CoV-1 counterpart, binds Angiotensin-Converting Enzyme 2 (ACE2), but with much higher affinity and faster binding kinetics through the receptor binding domain (RBD) located in the C-terminal region of S1 (8). Based on structural biology studies, the RBD can be oriented either in the up/standing or down/lying state with the up/standing state associated with higher pathogenicity (9). Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy (10). It has been demonstrated that the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (11, 12). While the SARS-CoV-2 D614G variant is currently the most prevalent form of the virus, the mechanism of action has not been identified (13).

References
  1. Wu, F. et al. (2020) Nature 579:265.
  2. Tortorici, M.A. and D. Veesler (2019). Adv. Virus Res. 105:93.
  3. Bosch, B.J. et al. (2003). J. Virol. 77:8801.
  4. Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871.
  5. Millet, J.K. and G.R. Whittaker (2015) Virus Res. 202:120.
  6. Korber, et al. (2020) Cell 182, 812.
  7. Zhang, L. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.06.12.148726v1.
  8. Ortega, J.T. et al. (2020) EXCLI J. 19:410.
  9. Yuan, Y. et al. (2017) Nat. Commun. 8:15092.
  10. Tai, W. et al. (2020) Cell. Mol. Immunol. https://doi.org/10.1016/j.it.2020.03.007.
  11. Wang, X. et al. (2020) https://doi.org/10.1038/s41423-020-0424-9.
  12. Wang, K. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1.
  13. Isabel, et al. (2020) Sci Rep 10, 14031. https://doi.org/10.1038/s41598-020-70827-z.
Long Name
Spike Protein
Entrez Gene IDs
918758 (HCoV-229E); 2943499 (HCoV-NL63); 39105218 (HCoV-OC43); 37616432 (MERS-CoV); 1489668 (SARS-CoV); 43740568 (SARS-CoV-2)
Alternate Names
2019-nCoV S Protein; 2019-nCoV Spike; COVID-19 Spike; E2; Human coronavirus spike glycoprotein; Peplomer protein; S glycoprotein; S Protein; SARS-COV-2 S protein; SARS-COV-2 Spike glycoprotein; SARSCOV2 Spike protein; SARS-CoV-2; Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein; Spike glycoprotein; Spike; surface glycoprotein

Citation for Recombinant SARS-CoV-2 D614G Spike His-tag, Protein CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1

  1. Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19
    Authors: Ford, ES;Mayer-Blackwell, K;Jing, L;Laing, KJ;Sholukh, AM;St Germain, R;Bossard, EL;Xie, H;Pulliam, TH;Jani, S;Selke, S;Burrow, CJ;McClurkan, CL;Wald, A;Greninger, AL;Holbrook, MR;Eaton, B;Eudy, E;Murphy, M;Postnikova, E;Robins, HS;Elyanow, R;Gittelman, RM;Ecsedi, M;Wilcox, E;Chapuis, AG;Fiore-Gartland, A;Koelle, DM;
    Nature immunology
    Species: Human
    Sample Types: Transduced Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant SARS-CoV-2 D614G Spike His-tag, Protein CF

There are currently no reviews for this product. Be the first to review Recombinant SARS-CoV-2 D614G Spike His-tag, Protein CF and earn rewards!

Have you used Recombinant SARS-CoV-2 D614G Spike His-tag, Protein CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review